Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bempedoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY known ✓ | P53396 | 1/20 | 0.57 |
| ▸ | ACACB | O00763 | 1/20 | 1.00 |
| ▸ | ACACA | Q13085 | 1/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186052 | 1.00 | ACACB (1.00) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL23348922 | 1.00 | ACACB (1.00) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL186486 | 0.98 | ACACB (0.96) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL205270 | 0.98 | ACACB (0.96) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL25936778 | 0.94 | ACACB (0.89) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL12094483 | 0.94 | ACACB (0.88) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL3748635 | 0.94 | ACACB (0.88) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL2737120 | 0.93 | ACACB (0.86) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL186401 | 0.93 | ACACB (0.86) | ACACBACACAACLYFFAR1FFAR4 | |
| SCHEMBL12092725 | 0.93 | ACACB (0.86) | ACACBACACAACLYFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1099 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743069-A1 | STABLE SOLID DISPERSIONS OF SALCAPROZATE WITH VARIOUS ACTIVE PHARMACEUTICAL INGREDIENTS | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2026-05-20 | — | — | EP | claimed |
| EP-4739301-A1 | COMPOSITIONS CONTAINING, AND COMBINATION THERAPIES USING BEMPEDOIC ACID AND A GLP-1 RECEPTOR AGONIST | Esperion Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260043031-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ADENYLATE CYCLASE 9 (AC9) | INST DE CARDIOLOGIE DE MONTREAL (CA) | 2026-02-12 | — | — | US | claimed |
| US-12516013-B2 | Crystalline forms of sodium salt of Bempedoic acid | SYNTHON B.V. (NL) | 2026-01-06 | — | — | US | claimed |
| WO-2025202988-A1 | CONCOMITANT TREATMENT WITH TTFIELDS AND HGM-COA REDUCTASE INHIBITORS | NOVOCURE GMBH (CH) | 2025-10-02 | — | — | WO | claimed |
| US-20250303156-A1 | CONCOMITANT TREATMENT OF TTFIELDS AND HMG-CO A REDUCTASE INHIBITORS | NOVOCURE GMBH (CH) | 2025-10-02 | — | — | US | claimed |
| US-20250302750-A1 | PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID | RENATA PHARMACEUTICALS (IRELAND) LIMITED (IE) | 2025-10-02 | — | — | US | claimed |
| EP-4599048-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| WO-2025151504-A1 | COMPOSITIONS AND METHODS FOR REDUCING RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENT | ABCENTRA, LLC (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4569090-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| CN-111170855-A | Compound and method for synthesizing 8-hydroxy-2, 2,14, 14-tetramethylpentadecanedioic acid by using same | 奥锐特药业(天津)有限公司 | 2020-05-19 | — | — | CN | claimed |
| WO-2018170316-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-09-20 | — | — | WO | claimed |
| US-9855240-B2 | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2018-01-02 | — | — | US | claimed |
| US-9662307-B2 | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2017-05-30 | — | — | US | claimed |
| US-20170119721-A1 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2017-05-04 | — | — | US | claimed |
| US-20170100363-A9 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2017-04-13 | — | — | US | claimed |
| US-20140256809-A1 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2014-09-11 | — | — | US | claimed |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2011-01-06 | — | — | US | claimed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256809-A1 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF | ALOX5, ALOX15, ALOX12 | ACLY 1207/4885ACACB 478/4885ACACA 286/4885 |
| US-20170119721-A1 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF | ALOX5, ALOX15, ALOX12 | ACLY 1207/4885ACACB 478/4885ACACA 286/4885 |
| US-20260043031-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ADENYLATE CYCLASE 9 (AC9) | LDLR, ADCY9, ADCY6 | ACLY 768/4885ACACB 139/4885ACACA 205/4885 |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACLY 1714/4885ACACB 543/4885ACACA 495/4885 |
| US-20170100363-A9 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF | ALOX5, ALOX15, ALOX12 | ACLY 1207/4885ACACB 478/4885ACACA 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.